Phase 1Completed
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of SR Exenatide (PT302) After Subcutaneous Injection in Healthy Male Volunteers
- Sponsor
- Peptron, Inc. (Industry)
- Enrolment
- 34 enrolled
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SR Exenatide (PT302); Placebo
- Ages
- adults
- Registry
- NCT00964262
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of SR exenatide (PT302) in healthy subjects.
Primary outcomes
- To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection
History
Last registry update
Primary completion
Registered
Started